Trials / Withdrawn
WithdrawnNCT03455777
Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
A Phase 2 Open-Label Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Patients With Homozygous Familial Hypercholesterolemia (HoFH)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Akcea Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3- LRX for reduction of low density lipoprotein cholesterol (LDL-C) levels in patients with Homozygous Familial Hypercholesterolemia (HoFH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AKCEA-ANGPTL3-LRX | Single open-label cohort |
Timeline
- Start date
- 2018-04-12
- Primary completion
- 2018-09-30
- Completion
- 2018-12-31
- First posted
- 2018-03-07
- Last updated
- 2018-12-03
Locations
1 site across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03455777. Inclusion in this directory is not an endorsement.